Dr. Timothy J. Wierzbicki, MD

Dr. Wierzbicki practices at Orlando VA Medical Center in Orlando, Florida, part of Veterans Health Administration.

Dr. Wierzbicki's NPI, 1134145741, was assigned on July 15, 2006. Dr. Wierzbicki graduated from Indiana University School Of Medicine in 1996. Dr. Wierzbicki holds Florida license ME80334.

Dr. Wierzbicki's primary practice is Orlando VA Medical Center, at 13800 Veterans Way, Orlando, FL 32827 in Orange County. The practice phone is (407) 631-1000.

Dr. Wierzbicki's primary practice is Orlando VA Medical Center in Orlando, Florida, part of Veterans Health Administration. Dr. Wierzbicki is also affiliated with AdventHealth Daytona Beach. The medical group on file is Ability Rehabilitation. Dmand AI also links Dr. Wierzbicki to 3 more hospitals, 2 group practices and clinics, 1 physician office, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wierzbicki practices, 9 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Wierzbicki's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Wierzbicki is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Wierzbicki's licenses on file in 2 states: Florida and Ohio.

Dmand AI lists acute mini-stroke (TIA), alzheimer's disease, carpal tunnel syndrome, cerebrovascular disease, encephalopathy, epilepsy, essential tremor and fibromyalgia and chronic pain among the conditions Dr. Wierzbicki treats.

CMS data shows 1,766 Medicare services from Dr. Wierzbicki across 8 procedure codes in 2024, for 693 Medicare patients. Medicare paid $300,942 for them. Every service was in an office.

CMS counts 693 Medicare patients who saw Dr. Wierzbicki in 2024. The largest group is 75 to 84, with 296 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wierzbicki's median patient age at 75, with 58% women.

In 2024, Dr. Wierzbicki wrote 5,434 Medicare Part D claims for 862 patients. 93% of them were for generic drugs. CMS names the drug for 5,210 of them, across 57 drugs with 11 or more claims each, at $1,389,126 in total drug cost. In 2023, CMS named 4,382 claims across 49 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Wierzbicki for performance year 2024, reported individually. Dr. Wierzbicki accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Wierzbicki to 36 clinical trials, 12 of them phase 3 studies. Conditions studied include Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS and Multiple Sclerosis, Chronic Progressive. Purdue Pharma LP sponsors the most, 5.

CMS Open Payments shows 165 general payments to Dr. Wierzbicki from 41 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 89% of the total. Abbvie Inc. paid the most, $358. It also lists 2 research payments totaling $15,768 from 2020 to 2021.

Dr. Wierzbicki graduated from Indiana University School Of Medicine in 1996. Dr. Wierzbicki is a member of AAN and AMA.

Dr. Wierzbicki is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.